Sigilon Therapeutics, Inc. (NASDAQ:SGTX – Get Rating) was the recipient of a large growth in short interest during the month of May. As of May 31st, there was short interest totalling 664,500 shares, a growth of 25.2% from the May 15th total of 530,600 shares. Based on an average trading volume of 99,100 shares, the days-to-cover ratio is currently 6.7 days. Approximately 4.7% of the company’s shares are sold short.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC lifted its holdings in Sigilon Therapeutics by 177.3% during the 4th quarter. Citadel Advisors LLC now owns 10,896 shares of the company’s stock valued at $30,000 after buying an additional 24,996 shares in the last quarter. Rhumbline Advisers bought a new stake in Sigilon Therapeutics during the 4th quarter valued at about $30,000. Acadian Asset Management LLC bought a new stake in Sigilon Therapeutics during the 4th quarter valued at about $30,000. American International Group Inc. lifted its holdings in Sigilon Therapeutics by 101.3% during the 3rd quarter. American International Group Inc. now owns 8,321 shares of the company’s stock valued at $47,000 after buying an additional 4,187 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in Sigilon Therapeutics during the 3rd quarter valued at about $77,000. Institutional investors own 58.41% of the company’s stock.
Sigilon Therapeutics stock opened at $0.85 on Friday. The firm has a 50-day moving average price of $1.01 and a 200-day moving average price of $1.66. The firm has a market capitalization of $27.54 million, a PE ratio of -0.38 and a beta of 0.91. Sigilon Therapeutics has a 12-month low of $0.73 and a 12-month high of $12.01.
About Sigilon Therapeutics (Get Rating)
Sigilon Therapeutics, Inc, a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes.
- Get a free copy of the StockNews.com research report on Sigilon Therapeutics (SGTX)
- The Analysts Upgrade… Retail Stocks?
- Dividend Stocks and Your Roth IRA
- The Q2 Earnings Season Could Be A Bloodbath
- Commercial Metals Company Is Ready To Rebound
- The Institutions Turn The Tide For Jabil
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Sigilon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sigilon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.